Clinical Pharmacology & Therapeutics · 2004 · 63 citations · 21 references
MedicinePharmacologyPharmacotherapyAntimicrobial PharmacologyChemotherapyClinical PharmacologyCardiac MedicationsCardiovascular Drug SafetyPotentially Inappropriate MedicationsClinical Pharmacology EvidenceDrug-induced Arrhythmia SusceptibilityDrug-induced ArrhythmiasFluoroquinolone AntibioticsSystemic Lupus Erythematosus Associations
The fluoroquinolone antibiotics sparfloxacin, grepafloxacin, gatifloxacin, and levofloxacin have been reported to cause torsades de pointes. Pre-existing risk factors increase vulnerability to this life-threatening arrhythmia. In a 65-year-old woman with a history of hypertension, coronary artery disease, systemic lupus erythematosus, and osteomyelitis, QTc interval prolongation (605 ms) and torsades de pointes developed after the initiation of levofloxacin, 250 mg intravenously once daily. The patient was hypokalemic and mildly hypomagnesemic before the initiation of levofloxacin and at the time of occurrence of torsades de pointes. The QTc interval decreased to 399 ms within hours of discontinuation of the levofloxacin, after which she had no further arrhythmias. In this and the majority of other published cases of fluoroquinolone-associated torsades de pointes, patients had at least 1 risk factor for the arrhythmia, and most had multiple risk factors. Fluoroquinolone antibiotics should be avoided whenever possible in patients with pre-existing risk factors for torsades de pointes.
21
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes
Ping Yang, Hideaki Kanki, Benoît Drolet et al. · Circulation · 2002 · 552 citations